| Market Cap | 3.13B | P/E | - | EPS this Y | 24.00% | Ern Qtrly Grth | - |
| Income | -296.9M | Forward P/E | -12.52 | EPS next Y | 20.70% | 50D Avg Chg | -5.00% |
| Sales | 200.43M | PEG | 2.42 | EPS past 5Y | - | 200D Avg Chg | 17.00% |
| Dividend | N/A | Price/Book | 4.88 | EPS next 5Y | -1.00% | 52W High Chg | -14.00% |
| Recommedations | 2.40 | Quick Ratio | 8.12 | Shares Outstanding | 272.36M | 52W Low Chg | 162.00% |
| Insider Own | 1.85% | ROA | -10.84% | Shares Float | 270.84M | Beta | 1.98 |
| Inst Own | 94.54% | ROE | -44.28% | Shares Shorted/Prior | 52.82M/49.05M | Price | 12.52 |
| Gross Margin | 30.38% | Profit Margin | -148.13% | Avg. Volume | 3,583,696 | Target Price | 4.67 |
| Oper. Margin | -209.82% | Earnings Date | Jul 31 | Volume | 6,211,175 | Change | -6.15% |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
| Morgan Stanley | Equal-Weight | May 15, 24 |
| Piper Sandler | Neutral | May 13, 24 |
| Barclays | Equal-Weight | May 10, 24 |
| JP Morgan | Neutral | Apr 22, 24 |
| Goldman Sachs | Neutral | Apr 19, 24 |
| Bernstein | Outperform | Apr 18, 24 |
| Goldman Sachs | Neutral | Apr 18, 24 |
| Scotiabank | Sector Outperform | Apr 18, 24 |
| TD Cowen | Buy | Apr 17, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Van Oene Mark | See Remarks See Remarks | Jan 09 | Sell | 7.773 | 31,012 | 241,056 | 910,171 | 01/10/24 |
| Kim Susan G. | See Remarks See Remarks | Sep 29 | Sell | 8.437 | 19,257 | 162,471 | 306,085 | 09/29/23 |
| Eidel Jeff | See Remarks See Remarks | Aug 17 | Sell | 10.597 | 25,936 | 274,844 | 444,666 | 08/18/23 |
| Farmer Michele | See Remarks See Remarks | May 18 | Sell | 12.59 | 5,165 | 65,027 | 107,577 | 05/19/23 |
| Kim Susan G. | See Remarks See Remarks | Feb 17 | Sell | 10.271 | 907 | 9,316 | 162,581 | 02/22/23 |
| HENRY CHRISTIAN O | See Remarks See Remarks | Feb 17 | Sell | 10.271 | 1,530 | 15,715 | 642,021 | 02/22/23 |
| Van Oene Mark | See Remarks See Remarks | Jan 10 | Sell | 9.534 | 26,722 | 254,768 | 640,808 | 01/11/23 |
| Kim Susan G. | See Remarks See Remarks | Sep 29 | Sell | 5.614 | 12,968 | 72,802 | 163,488 | 10/03/22 |
| MOHR MARSHALL | Director Director | Jun 10 | Option | 1.83 | 35,000 | 64,050 | 60,000 | 06/13/22 |
| Farmer Michele | See Remarks See Remarks | May 18 | Sell | 5.547 | 3,573 | 19,819 | 60,354 | 05/20/22 |
| ORDONEZ KATHY | Director Director | Feb 16 | Sell | 11.5 | 3,280 | 37,720 | 18,595 | 02/17/22 |
| MOHR MARSHALL | Director Director | Jan 14 | Option | 3.57 | 25,000 | 89,250 | 25,000 | 01/19/22 |
| Van Oene Mark | Chief Operating Offi.. Chief Operating Officer | Jan 11 | Sell | 14.23 | 41,480 | 590,260 | 293,520 | 01/13/22 |
| Fromen Peter | Chief Commercial Off.. Chief Commercial Officer | Jan 11 | Sell | 14.3 | 19,720 | 281,996 | 140,280 | 01/13/22 |
| Ericson William W. | Director Director | May 26 | Option | 6.21 | 37,500 | 232,875 | 37,500 | 05/26/21 |
| Hunkapiller Michael | Director Director | Feb 26 | Option | 6.27 | 605,804 | 3,798,391 | 1,187,782 | 02/26/21 |
| Hunkapiller Michael | Director Director | Feb 26 | Sell | 34.83 | 605,804 | 21,100,153 | 848,405 | 02/26/21 |
| ORDONEZ KATHY | Director Director | Feb 18 | Option | 5.18 | 185,879 | 962,853 | 242,646 | 02/18/21 |
| ORDONEZ KATHY | Director Director | Feb 18 | Sell | 48.35 | 220,771 | 10,674,278 | 21,875 | 02/18/21 |
| LIVINGSTON RANDALL S | Director Director | Feb 17 | Option | 4.98 | 67,500 | 336,150 | 67,500 | 02/17/21 |
| LIVINGSTON RANDALL S | Director Director | Feb 17 | Sell | 48.07 | 67,500 | 3,244,725 | 02/17/21 | |
| Botstein David | Director Director | Feb 17 | Option | 4.58 | 160,000 | 732,800 | 160,000 | 02/17/21 |
| Botstein David | Director Director | Feb 17 | Sell | 49.85 | 160,000 | 7,976,000 | 02/17/21 | |
| Hunkapiller Michael | Director Director | Jan 27 | Option | 6.14 | 125,406 | 769,993 | 973,811 | 01/27/21 |
| Hunkapiller Michael | Director Director | Jan 27 | Sell | 36.53 | 125,406 | 4,581,081 | 848,405 | 01/27/21 |
| Hunkapiller Michael | Director Director | Jan 22 | Option | 4.21 | 574,594 | 2,419,041 | 999,262 | 01/22/21 |
| Hunkapiller Michael | Director Director | Jan 22 | Sell | 37.87 | 624,404 | 23,646,179 | 848,405 | 01/22/21 |
| Hunkapiller Michael | Director Director | Dec 23 | Option | 4.72 | 700,000 | 3,304,000 | 1,262,666 | 12/23/20 |
| Hunkapiller Michael | Director Director | Dec 23 | Sell | 23.88 | 700,000 | 16,716,000 | 898,215 | 12/23/20 |